Compare OSUR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | CRDF |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.6M | 67.1M |
| IPO Year | 2000 | 2012 |
| Metric | OSUR | CRDF |
|---|---|---|
| Price | $3.55 | $0.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.50 | ★ $6.28 |
| AVG Volume (30 Days) | ★ 638.2K | 346.5K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $167,064,000.00 | $365,993.00 |
| Revenue This Year | $4.64 | N/A |
| Revenue Next Year | $9.04 | $5.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $2.08 | $0.71 |
| 52 Week High | $4.58 | $3.31 |
| Indicator | OSUR | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 49.74 |
| Support Level | $2.78 | $0.77 |
| Resistance Level | $4.11 | $1.13 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 28.88 | 70.96 |
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.